What is Hummingbird Bioscience?
Hummingbird Bioscience is an innovative clinical-stage biotech company established in 2015 and headquartered in Texas, United States. The company is dedicated to developing precision therapies targeting hard-to-drug biological mechanisms to enhance patient treatment outcomes. By focusing on novel approaches to complex diseases, Hummingbird Bioscience aims to address significant unmet medical needs within the pharmaceutical sector. Its strategic focus on precision medicine and difficult targets places it at the forefront of therapeutic innovation.
How much funding has Hummingbird Bioscience raised?
Hummingbird Bioscience has raised a total of $275M across 3 funding rounds:
Series B
$25M
Series C
$125M
Series C
$125M
Series B (2020): $25M with participation from heritascapital.com, GNTech Venture Capital, Delian Capital, Mirae Asset Global Investments, SK Holdings Co., Ltd., and SEED Capital
Series C (2021): $125M led by Octagon Capital, Frazier Healthcare Partners, Amgen Ventures, Edbi, and Novo Holdings
Series C (2025): $125M supported by Altrium, Edbi, Droia, Novo Holdings, Polaris Partners, Pureos Bioventures, Affinity Asset Advisors, Morningside Venture Capital, Amgen, Ally Bridge Group, Frazier Healthcare Partners, Singapore Economic Development Board, and Octagon Capital Group
Key Investors in Hummingbird Bioscience
Altrium
Altrium is a technology firm specializing in Generative AI LLM solutions and enterprise APIs, partnering with Fortune 1000 companies and startups to deliver innovative software and accelerate client growth through cutting-edge technology.
Edbi
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991, aiming to create value and empower businesses through strategic investments in biotechnology, fintech, and telecommunications.
Droia
Droia Ventures is a specialist investor dedicated to making an impact and saving patient lives by investing in the most promising life science companies.
What's next for Hummingbird Bioscience?
The substantial enterprise-level funding, including the recent major strategic investment, indicates that Hummingbird Bioscience is likely in a scaling phase, poised to advance its clinical pipeline and expand its research and development capabilities. This capital infusion will be critical for progressing its precision therapies through clinical trials and potentially towards commercialization. The company's ability to attract significant investment from prominent life science backers suggests strong confidence in its scientific approach and therapeutic potential, paving the way for future milestones and market impact.
See full Hummingbird Bioscience company page
